These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 20512989

  • 1. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
    Yu J, Shen B, Chu ES, Teoh N, Cheung KF, Wu CW, Wang S, Lam CN, Feng H, Zhao J, Cheng AS, To KF, Chan HL, Sung JJ.
    Hepatology; 2010 Jun; 51(6):2008-19. PubMed ID: 20512989
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro.
    Wang J, Zhao J, Chu ES, Mok MT, Go MY, Man K, Heuchel R, Lan HY, Chang Z, Sung JJ, Yu J.
    J Pathol; 2013 Aug; 230(4):441-52. PubMed ID: 23625826
    [Abstract] [Full Text] [Related]

  • 3. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
    Cheung KF, Zhao J, Hao Y, Li X, Lowe AW, Cheng AS, Sung JJ, Yu J.
    Cancer; 2013 Mar 15; 119(6):1217-26. PubMed ID: 23212831
    [Abstract] [Full Text] [Related]

  • 4. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Röcken C, Malfertheiner P, Farrell GC.
    Hepatology; 2006 Jan 15; 43(1):134-43. PubMed ID: 16374840
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro.
    Yu J, Zhang S, Chu ES, Go MY, Lau RH, Zhao J, Wu CW, Tong L, Zhao J, Poon TC, Sung JJ.
    Int J Biochem Cell Biol; 2010 Jun 15; 42(6):948-57. PubMed ID: 20156580
    [Abstract] [Full Text] [Related]

  • 6. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
    Shim J, Kim BH, Kim YI, Kim KY, Hwangbo Y, Jang JY, Dong SH, Kim HJ, Chang YW, Chang R.
    Int J Oncol; 2010 Jan 15; 36(1):223-31. PubMed ID: 19956851
    [Abstract] [Full Text] [Related]

  • 7. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
    Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J.
    Br J Cancer; 2012 Apr 24; 106(9):1486-94. PubMed ID: 22472882
    [Abstract] [Full Text] [Related]

  • 8. Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma.
    Wu CW, Farrell GC, Yu J.
    J Gastroenterol Hepatol; 2012 Nov 24; 27(11):1665-9. PubMed ID: 22742931
    [Abstract] [Full Text] [Related]

  • 9. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS, Chen WC, Bai X, Wang YD.
    J Dig Dis; 2007 May 24; 8(2):82-8. PubMed ID: 17532820
    [Abstract] [Full Text] [Related]

  • 10. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
    Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC.
    Clin Cancer Res; 2008 Jul 01; 14(13):4045-52. PubMed ID: 18593980
    [Abstract] [Full Text] [Related]

  • 11. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
    Kim KR, Choi HN, Lee HJ, Baek HA, Park HS, Jang KY, Chung MJ, Moon WS.
    Oncol Rep; 2007 Oct 01; 18(4):825-32. PubMed ID: 17786342
    [Abstract] [Full Text] [Related]

  • 12. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.
    Galli A, Ceni E, Mello T, Polvani S, Tarocchi M, Buccoliero F, Lisi F, Cioni L, Ottanelli B, Foresta V, Mastrobuoni G, Moneti G, Pieraccini G, Surrenti C, Milani S.
    Hepatology; 2010 Aug 01; 52(2):493-505. PubMed ID: 20683949
    [Abstract] [Full Text] [Related]

  • 13. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
    Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ.
    Cancer Res; 2005 Mar 15; 65(6):2251-9. PubMed ID: 15781638
    [Abstract] [Full Text] [Related]

  • 14. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
    Morosetti R, Servidei T, Mirabella M, Rutella S, Mangiola A, Maira G, Mastrangelo R, Koeffler HP.
    Int J Oncol; 2004 Aug 15; 25(2):493-502. PubMed ID: 15254749
    [Abstract] [Full Text] [Related]

  • 15. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
    Yuan Y, Zhang A, Huang S, Ding G, Chen R.
    Am J Physiol Renal Physiol; 2011 Feb 15; 300(2):F393-402. PubMed ID: 21123490
    [Abstract] [Full Text] [Related]

  • 16. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
    Cao LQ, Shao ZL, Liang HH, Zhang DW, Yang XW, Jiang XF, Xue P.
    Cancer Lett; 2015 Apr 01; 359(1):127-35. PubMed ID: 25592041
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
    Yoshizawa K, Cioca DP, Kawa S, Tanaka E, Kiyosawa K.
    Cancer; 2002 Nov 15; 95(10):2243-51. PubMed ID: 12412180
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
    Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thulé PM, Sutliff RL, Hart CM.
    Vascul Pharmacol; 2007 Jun 15; 46(6):456-62. PubMed ID: 17337254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.